Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Target Price at $9.75

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have earned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $9.75.

Several equities research analysts have issued reports on ACRS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Aclaris Therapeutics in a research report on Wednesday.

Aclaris Therapeutics Trading Down 2.3%

Shares of ACRS stock opened at $3.43 on Friday. Aclaris Therapeutics has a 12 month low of $1.05 and a 12 month high of $4.89. The company has a market capitalization of $371.64 million, a P/E ratio of -2.49 and a beta of 0.41. The stock has a 50 day moving average of $3.09 and a two-hundred day moving average of $2.34.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. The business had revenue of $3.30 million for the quarter, compared to analysts’ expectations of $1.59 million. Aclaris Therapeutics had a negative return on equity of 39.73% and a negative net margin of 900.01%. Sell-side analysts predict that Aclaris Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aclaris Therapeutics

Large investors have recently modified their holdings of the stock. AXQ Capital LP acquired a new position in shares of Aclaris Therapeutics in the 3rd quarter worth approximately $27,000. China Universal Asset Management Co. Ltd. bought a new stake in Aclaris Therapeutics in the fourth quarter valued at $53,000. ProShare Advisors LLC acquired a new position in Aclaris Therapeutics during the second quarter worth $26,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Aclaris Therapeutics during the second quarter valued at $28,000. Finally, XTX Topco Ltd bought a new position in shares of Aclaris Therapeutics during the second quarter valued at $34,000. 98.34% of the stock is currently owned by institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.